tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Madrigal Pharmaceuticals Holds 2025 Annual Stockholders Meeting
PremiumCompany AnnouncementsMadrigal Pharmaceuticals Holds 2025 Annual Stockholders Meeting
28d ago
Positive CHMP Opinion Boosts Madrigal Pharmaceuticals’ Prospects for Rezdiffra in EU Market
Premium
Ratings
Positive CHMP Opinion Boosts Madrigal Pharmaceuticals’ Prospects for Rezdiffra in EU Market
29d ago
Madrigal Pharmaceuticals receives positive CHMP opinion for resmetirom
Premium
The Fly
Madrigal Pharmaceuticals receives positive CHMP opinion for resmetirom
29d ago
Madrigal announces two-year results from Phase 3 MAESTRO-NAFLD-1 trial
PremiumThe FlyMadrigal announces two-year results from Phase 3 MAESTRO-NAFLD-1 trial
2M ago
Short Report: Bears sell into sharp rally in Hims & Hers
Premium
The Fly
Short Report: Bears sell into sharp rally in Hims & Hers
2M ago
Madrigal Pharmaceuticals: Strong Market Performance and Growth Potential with Rezdiffra Leading the NASH Market
Premium
Ratings
Madrigal Pharmaceuticals: Strong Market Performance and Growth Potential with Rezdiffra Leading the NASH Market
2M ago
Madrigal’s Earnings Call: Rezdiffra’s Success and Future Plans
PremiumCompany AnnouncementsMadrigal’s Earnings Call: Rezdiffra’s Success and Future Plans
3M ago
Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
Premium
Ratings
Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
3M ago
Madrigal Pharmaceuticals reports Q1 EPS ($3.32), consensus ($3.79)
Premium
The Fly
Madrigal Pharmaceuticals reports Q1 EPS ($3.32), consensus ($3.79)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100